PMID- 36994133
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230331
IS  - 2424-1741 (Electronic)
IS  - 2189-3926 (Print)
IS  - 2189-3926 (Linking)
VI  - 7
IP  - 1
DP  - 2021
TI  - Efficacy of Add-on Therapy with Carvedilol and the Direct Renin Inhibitor 
      Aliskiren for Improving Cardiac Sympathetic Nerve Activity, Cardiac Function, 
      Symptoms, Exercise Capacity and Brain Natriuretic Peptide in Patients with 
      Dilated Cardiomyopathy.
PG  - 33-42
LID - 10.17996/anc.21-00139 [doi]
AB  - Purpose/Method: Aliskiren is a direct renin inhibitor that has been reported to 
      be effective for CHF, but the usefulness of combined therapy with carvedilol and 
      aliskiren has not been reported. Forty-four patients with dilated cardiomyopathy 
      (DCM) were randomized into a group receiving add-on therapy with carvedilol plus 
      aliskiren and another group receiving carvedilol alone for 6 months. Nuclear 
      imagings with (123)I-Metaiodobenzylguanidine (MIBG) and (99m)Tc-Sestamibi were 
      performed. Exercise capacity using a specific activity scale (SAS) and the New 
      York Heart Association (NYHA) class were evaluated. Cardiac sympathetic nerve 
      activity was evaluated by (123)I-MIBG imaging, with the delayed 
      heart-to-mediastinum activity ratio (H/M), delayed total defect score (TDS), and 
      washout rate (WR). Results: Combined add-on therapy with carvedilol and aliskiren 
      improved several parameters much more than carvedilol alone (p<0.05) with respect 
      to TDS, ejection fraction (EF), NYHA, SAS on 6 months and the changes in TDS, EF, 
      end-diastolic volume and brain natriuretic peptide (BNP). Conclusion: Add-on 
      therapy with carvedilol and aliskiren is more effective than carvedilol alone for 
      improving cardiac sympathetic nerve activity, cardiac function, symptoms, 
      exercise capacity, and brain natriuretic peptide in patients with DCM.
CI  - (c) The Japanese Society of Nuclear Cardiology 2021.
FAU - Toyama, Takuji
AU  - Toyama T
AD  - Division of Cardiology, Toyama Cardiovascular Clinic, Maebashi, Japan.
FAU - Kasama, Shu
AU  - Kasama S
AD  - Clinical Research Center, Nara Medical University Graduate School of Medicine, 
      Nara, Japan.
FAU - Miyaishi, Yusuke
AU  - Miyaishi Y
AD  - Division of Cardiology, Gunma Prefectural Cardiovascular Center, Maebashi, Japan.
FAU - Kan, Hakuken
AU  - Kan H
AD  - Division of Cardiology, Gunma Prefectural Cardiovascular Center, Maebashi, Japan.
FAU - Yamashita, Eiji
AU  - Yamashita E
AD  - Division of Cardiology, Gunma Prefectural Cardiovascular Center, Maebashi, Japan.
FAU - Kawaguchi, Ren
AU  - Kawaguchi R
AD  - Division of Cardiology, Gunma Prefectural Cardiovascular Center, Maebashi, Japan.
FAU - Adachi, Hitoshi
AU  - Adachi H
AD  - Division of Cardiology, Gunma Prefectural Cardiovascular Center, Maebashi, Japan.
FAU - Hoshizaki, Hiroshi
AU  - Hoshizaki H
AD  - Division of Cardiology, Gunma Prefectural Cardiovascular Center, Maebashi, Japan.
FAU - Ohshima, Shigeru
AU  - Ohshima S
AD  - Division of Cardiology, Gunma Prefectural Cardiovascular Center, Maebashi, Japan.
LA  - eng
PT  - Journal Article
DEP - 20210831
PL  - Japan
TA  - Ann Nucl Cardiol
JT  - Annals of nuclear cardiology
JID - 101747118
PMC - PMC10040940
OTO - NOTNLM
OT  - 123I-metaiodobenzylguanidine imaging
OT  - Aliskiren
OT  - Brain natriuretic peptide
OT  - Cardiac sympathetic nerve activity
OT  - Carvedilol
OT  - Dilated cardiomyopathy
COIS- The authors have no conflicts of interest to declare in relation to this article.
EDAT- 2021/01/01 00:00
MHDA- 2021/01/01 00:01
PMCR- 2021/01/01
CRDT- 2023/03/30 03:01
PHST- 2021/01/06 00:00 [received]
PHST- 2021/03/16 00:00 [revised]
PHST- 2021/03/25 00:00 [accepted]
PHST- 2021/01/01 00:01 [medline]
PHST- 2023/03/30 03:01 [entrez]
PHST- 2021/01/01 00:00 [pubmed]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.17996/anc.21-00139 [doi]
PST - ppublish
SO  - Ann Nucl Cardiol. 2021;7(1):33-42. doi: 10.17996/anc.21-00139. Epub 2021 Aug 31.